DK2074221T3 - Forbedrede fremgangsmåder til separation af streptococcus pneumoniae type 3 polysakkarider - Google Patents

Forbedrede fremgangsmåder til separation af streptococcus pneumoniae type 3 polysakkarider

Info

Publication number
DK2074221T3
DK2074221T3 DK07843999.9T DK07843999T DK2074221T3 DK 2074221 T3 DK2074221 T3 DK 2074221T3 DK 07843999 T DK07843999 T DK 07843999T DK 2074221 T3 DK2074221 T3 DK 2074221T3
Authority
DK
Denmark
Prior art keywords
lysate
methods
precipitation
cause
aggregation
Prior art date
Application number
DK07843999.9T
Other languages
English (en)
Inventor
Brian Douglas Bahler
Erik Heller Hughes
Tsu-Shun Lee
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2074221(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of DK2074221T3 publication Critical patent/DK2074221T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK07843999.9T 2006-10-10 2007-10-09 Forbedrede fremgangsmåder til separation af streptococcus pneumoniae type 3 polysakkarider DK2074221T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85066506P 2006-10-10 2006-10-10
PCT/US2007/080768 WO2008045852A2 (en) 2006-10-10 2007-10-09 Purification of streptococcus pneumoniae type 3 polysaccharides

Publications (1)

Publication Number Publication Date
DK2074221T3 true DK2074221T3 (da) 2010-09-06

Family

ID=39156240

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07843999.9T DK2074221T3 (da) 2006-10-10 2007-10-09 Forbedrede fremgangsmåder til separation af streptococcus pneumoniae type 3 polysakkarider

Country Status (18)

Country Link
US (1) US7659090B2 (da)
JP (1) JP5260531B2 (da)
KR (1) KR101467002B1 (da)
CN (2) CN102648979B (da)
AT (1) ATE473289T1 (da)
AU (1) AU2007307800C1 (da)
BR (2) BRPI0717834B8 (da)
CA (1) CA2665169C (da)
CL (1) CL2007002909A1 (da)
DE (1) DE602007007642D1 (da)
DK (1) DK2074221T3 (da)
ES (1) ES2346929T3 (da)
IL (2) IL197782A (da)
MX (1) MX2009003730A (da)
PT (1) PT2074221E (da)
RU (1) RU2460539C2 (da)
WO (1) WO2008045852A2 (da)
ZA (1) ZA200902502B (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
BRPI0922981A8 (pt) 2008-12-18 2019-11-26 Wyeth Llc método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae
ES2749952T3 (es) 2008-12-18 2020-03-24 Wyeth Llc Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
US20120052088A1 (en) 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
CN102094053B (zh) * 2010-11-26 2013-01-16 兰州生物制品研究所有限责任公司 肺炎链球菌c多糖的纯化方法
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
RU2606022C2 (ru) 2012-09-07 2017-01-10 Ск Кемикалс Ко., Лтд. Способ получения капсульного полисахарида с пневмококковым серотипом
US20150320852A1 (en) 2012-12-18 2015-11-12 Glaxosmithkline Biologicals Sa Conjugates for protecting against diphtheria and/or tetanus
PL3096786T3 (pl) 2014-01-21 2021-11-08 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
CN110859957B (zh) 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HUE062499T2 (hu) 2015-01-15 2023-11-28 Pfizer Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények
WO2016174683A1 (en) 2015-04-28 2016-11-03 Biological E Limited Method for separation of protein and other impurities from microbial capsular polysaccharides
MY182282A (en) 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031799A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
EP4656208A3 (en) 2017-01-31 2026-03-04 Merck Sharp & Dohme LLC Methods for making polysaccharide-protein conjugates
JP7680185B2 (ja) 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
JP7111799B2 (ja) 2017-07-05 2022-08-02 インベントプライズ リミテッド ライアビリティ カンパニー 溶菌酵素、接線流濾過、及びマルチモードクロマトグラフィを用いたワクチン生産のための多糖精製
US10702596B2 (en) 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
MX394768B (es) 2017-09-07 2025-03-21 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
ES3058336T3 (es) 2017-12-06 2026-03-10 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
EP3749357A4 (en) 2018-02-05 2022-04-20 Sanofi Pasteur, Inc. POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
DK3817775T3 (da) 2018-07-04 2024-09-16 Vaxcyte Inc Forbedringer i immunogene konjugater
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
PH12022550110A1 (en) 2019-07-31 2022-12-12 Sk Bioscience Co Ltd Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US12473379B2 (en) * 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
CN114555618A (zh) * 2019-10-01 2022-05-27 格礼卡姆股份公司 发酵液中中性寡糖的分离
CN119371566A (zh) * 2020-02-21 2025-01-28 辉瑞公司 糖类的纯化
US12497640B2 (en) * 2020-05-14 2025-12-16 Serum Institute Of India Private Limited Methods for simultaneous fragmentation and purification of bacterial polysaccharides
KR20230056727A (ko) 2020-08-26 2023-04-27 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
WO2022084852A1 (en) * 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP7804673B2 (ja) 2020-11-10 2026-01-22 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023403045A1 (en) 2022-12-01 2025-06-12 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20252774A1 (es) 2023-03-30 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20260015203A (ko) 2023-05-19 2026-02-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4413057A (en) * 1980-04-14 1983-11-01 Merck & Co., Inc. Group B streptococcal capsular polysaccharides
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
ATE459373T1 (de) * 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
AU2001245795B2 (en) * 2000-03-16 2005-07-28 The Children's Hospital Of Philadelphia Modulating production of pneumococcal capsular polysaccharide
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US20050220777A1 (en) * 2003-11-21 2005-10-06 Stefan Roos Selection of lactic acid bacteria enhancing the immune response against Streptococcus pneumoniae
CN101155833B (zh) * 2005-04-08 2011-04-20 惠氏公司 通过pH操作将污染物与肺炎链球菌多糖分离
EP1976857A4 (en) * 2006-01-13 2011-08-03 Baxter Int PROCESS FOR CLEANING POLYSACCHARIDES

Also Published As

Publication number Publication date
BR122019021950B1 (pt) 2021-01-05
BR122019021950B8 (pt) 2021-07-27
CN102648979A (zh) 2012-08-29
RU2009112453A (ru) 2010-11-20
IL197782A0 (en) 2011-08-01
US20080102498A1 (en) 2008-05-01
AU2007307800C1 (en) 2014-03-13
CA2665169C (en) 2017-02-21
PT2074221E (pt) 2010-09-06
IL233893A (en) 2017-04-30
CN101522906A (zh) 2009-09-02
CN102648979B (zh) 2014-05-14
BRPI0717834B1 (pt) 2020-05-19
IL233893A0 (en) 2014-09-30
KR101467002B1 (ko) 2014-12-01
CA2665169A1 (en) 2008-04-17
DE602007007642D1 (de) 2010-08-19
AU2007307800B2 (en) 2012-12-20
BRPI0717834B8 (pt) 2021-05-25
US7659090B2 (en) 2010-02-09
WO2008045852A2 (en) 2008-04-17
JP2010505963A (ja) 2010-02-25
ZA200902502B (en) 2010-03-31
IL197782A (en) 2014-08-31
ATE473289T1 (de) 2010-07-15
JP5260531B2 (ja) 2013-08-14
HK1174836A1 (en) 2013-06-21
AU2007307800A1 (en) 2008-04-17
CN101522906B (zh) 2012-05-30
MX2009003730A (es) 2009-04-22
ES2346929T3 (es) 2010-10-21
KR20090071629A (ko) 2009-07-01
WO2008045852A3 (en) 2008-06-19
RU2460539C2 (ru) 2012-09-10
CL2007002909A1 (es) 2008-04-18
BRPI0717834A2 (pt) 2014-06-10

Similar Documents

Publication Publication Date Title
DK2074221T3 (da) Forbedrede fremgangsmåder til separation af streptococcus pneumoniae type 3 polysakkarider
EA201070987A1 (ru) Очищенные гибридные белки иммуноглобулина и способы их очищения
MX2019005911A (es) Anticuerpos anti_cd137 novedosos y usos de estos.
MX2021003056A (es) Composiciones funcionales derivadas de frijol mungo.
ATE537188T1 (de) Serumalbuminbindende proteine
EP4512422A3 (en) Homogenous antibody populations
WO2007011363A3 (en) Binding domain fusion proteins
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
MX2010002269A (es) Composiciones y metodos que comprenden proteinas de union para adalimumab.
WO2007095506A8 (en) Oligosaccharide modification and labeling of proteins
PH12018502613B1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2010033279A3 (en) Antibodies with altered binding to fcrn and methods of using same
Saxena et al. Three phase partitioning as a novel method for purification of ragi (Eleusine coracana) bifunctional amylase/protease inhibitor
DK2086356T3 (da) Fremgangsmåde til opnåelse af knoldfrugtprotein-fraktioner med middelmolekylvægt, knoldfrugtprotein-fraktion og anvendelse af den samme
WO2008002663A3 (en) Immunogenic protein constructs
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
MX2022016322A (es) Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413.
WO2018132821A3 (en) Elastomeric proteins
WO2007028106A3 (en) Host cell lines for production of antibody constant region with enhanced effector function
WO2009043922A3 (en) Extracellular targets for alzheimer's disease
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity
Aguilar et al. Processing of soybean (Glycine max) extracts in aqueous two‐phase systems as a first step for the potential recovery of recombinant proteins
TW200506057A (en) Transient production of pharmaceutically important proteins in plants
WO2014194362A8 (en) Process for preparing apolipoprotein a-i (apo a-i)